DoD Multiple Sclerosis, Exploration - Hypothesis Development Award
ID: 353637Type: Posted
Overview

Buyer

Dept. of the Army -- USAMRAA (DOD-AMRAA)

Eligible Applicants

Unrestricted

Funding Category

Science and Technology and other Research and Development

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/353637
Timeline
    Description

    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the Multiple Sclerosis Exploration - Hypothesis Development Award (MSRP EHDA) to support innovative research in the field of multiple sclerosis (MS). This grant aims to facilitate the exploration of high-risk, high-gain concepts that could lead to groundbreaking advancements in MS research, with a focus on areas such as mechanisms of repair in the central nervous system and disease activity correlates. The program has an estimated total funding of $2 million, with up to $250,000 available per award over a two-year period, and applications are due in a two-step process, with pre-applications due by June 10, 2024, and full applications by October 7, 2024. Interested applicants can reach out to the CDMRP Help Desk at help@eBRAP.org for further assistance.

    Point(s) of Contact
    help@eBRAP.org
    Files
    Title
    Posted
    HT942524MSRPEHDA_GG.pdf
    The DOD Fiscal Year 2024 Multiple Sclerosis Exploration - Hypothesis Development Award facilitates innovative research pertinent to multiple sclerosis (MS) through a funding opportunity from the Department of Defense. This program targets various focus areas such as mechanisms of repair and protection in the central nervous system, disease activity correlates, symptom biology, and factors influencing MS progression. Funding of up to $250,000 is available over a two-year period, with a total budget of $20 million earmarked for the program. The proposal submission involves a two-step process, beginning with a pre-application due by June 10, 2024, followed by an invited full application by October 7, 2024. Eligibility includes both extramural and intramural organizations, with specific conditions for Principal Investigators (PIs), categorized into Established and New Investigators. The applications undergo a two-tier review process, assessing innovation, feasibility, and potential impact on MS research and patient care. The announcement emphasizes innovative approaches distinct from ongoing research and compliance with federal regulations regarding human and animal subjects. This funding initiative underscores the DOD's commitment to advancing health outcomes for service members and the public affected by MS.
    Similar Opportunities
    DoD Multiple Sclerosis, Early Investigator Research Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the FY24 Multiple Sclerosis Early Investigator Research Award (MSRP EIRA) to support innovative research focused on multiple sclerosis (MS) by early-stage investigators. This grant aims to foster the development of postdoctoral researchers with less than four years of experience, encouraging them to collaborate with experienced mentors to address critical needs in MS research, particularly in areas such as CNS repair, disease activity correlates, and MS symptomatology. The total funding available for this program is $1.6 million, with an expected five awards, each providing a maximum budget of $320,000 over two years. Key deadlines include a pre-application due by July 24, 2024, and a full application due by October 7, 2024. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.
    DoD Multiple Sclerosis, Investigator-Initiated Research Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the U.S. Army Medical Research and Materiel Command (USAMRAA), is offering a funding opportunity for the Fiscal Year 2024 Multiple Sclerosis Research Program (MSRP) via the Investigator-Initiated Research Award (IIRA). This grant aims to support innovative and high-impact research projects related to Multiple Sclerosis (MS), particularly those that can enhance patient care and quality of life, while excluding clinical trials. The program emphasizes research on central nervous system repair, disease progression correlates, symptom biology, and MS etiology, with a total funding pool of $6 million expected to yield approximately six awards, each up to $1 million over three years. Interested applicants must submit a pre-application by June 10, 2024, followed by a full application due by October 7, 2024, and can reach out to the CDMRP Help Desk at help@eBRAP.org for further assistance.
    DoD Multiple Sclerosis, Clinical Trial Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the FY24 Multiple Sclerosis Clinical Trial Award to support clinical trials aimed at improving treatment and management of multiple sclerosis (MS). This funding opportunity encourages innovative trials that may include new pharmacologic agents, devices, or emerging technologies, with a total estimated program funding of $8 million and the expectation of awarding three grants. Eligible applicants include unrestricted entities, and the funding levels are set at a maximum of $2 million for small-scale trials and $4 million for larger-scale studies, with a pre-application deadline of June 10, 2024, and a full application deadline of October 7, 2024. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or by phone at 301-682-5507.
    CDMRP Neurofibromatosis Exploration-Hypothesis Development Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the FY24 Neurofibromatosis Exploration-Hypothesis Development Award, aimed at funding innovative research related to neurofibromatosis (NF). This grant supports the exploration of high-risk, high-gain concepts to enhance understanding and treatment of NF1, NF2, and schwannomatosis, with an estimated total program funding of $1.12 million and the expectation to fund approximately seven projects. The application process is two-tiered, requiring pre-applications by September 12, 2024, and full applications by October 3, 2024, with a focus on innovation, research feasibility, and impact on NF research and patient care. Interested applicants can reach out to the CDMRP Help Desk at help@eBRAP.org for further assistance.
    Military Health System Research Program Notice of Funding Opportunity
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), has announced a Notice of Funding Opportunity (NOFO) for the Military Health System Research Program (MHSRP), aimed at enhancing research capabilities within the Military Health System (MHS). This program invites applications for research projects that focus on healthcare economics, quality, outcomes, variations, health readiness, and the impacts of policy changes, with the goal of fostering innovative health system research that supports both military and civilian healthcare. The total estimated funding for this initiative is $10 million, with applications due by September 20, 2024, following a Letter of Intent submission by June 10, 2024. Interested applicants can reach out to the DHA MHSR Program Mailbox at dha.ncr.j-9.mbx.hsr@health.mil for further information.
    DoD Arthritis, Focused Research Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the DoD Arthritis Focused Research Award (Funding Opportunity Number: HT942524ATRPFRA) to support innovative research aimed at improving patient care for individuals affected by arthritis. This grant encourages applications that explore high-risk, high-reward research addressing various types of arthritis, including osteoarthritis and rheumatoid arthritis, with a particular focus on the implications for military personnel and their families. The total funding available for FY24 is approximately $2.5 million, with individual project budgets capped at $750,000 for Research Level 2 and $500,000 for Research Level 1. Interested applicants must submit a pre-application by October 16, 2024, and a full application by October 30, 2024, and can reach out to the CDMRP Help Desk at help@eBRAP.org for further assistance.
    CDMRP Neurofibromatosis Early Investigator Research Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research Acquisition Activity (USAMRAA), is offering the Neurofibromatosis Early Investigator Research Award, a federal grant aimed at supporting innovative research in neurofibromatosis (NF). This opportunity is specifically designed for early-stage investigators to develop research projects under the guidance of experienced mentors, focusing on understanding, diagnosing, and treating NF1, NF2, and schwannomatosis disorders. With a total estimated program funding of $640,000 and an expected two awards, each grant will not exceed $200,000 over a performance period of two years. Interested applicants must submit their proposals by October 3, 2024, and can reach out to the CDMRP Help Desk at help@eBRAP.org for further assistance.
    DoD Combat Readiness - Medical, Translational Research Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the FY24 Combat Readiness - Medical Translational Research Award (CRRP TRA) to support high-impact translational research aimed at enhancing medical readiness for military personnel. This funding opportunity seeks proposals that address critical areas such as battlefield diagnostics, treatments for life-threatening injuries, and operational health threats, with an emphasis on projects that leverage existing resources and demonstrate clear relevance to military health. The total estimated funding for this initiative is approximately $3.3 million, with the expectation of awarding around three grants, and key deadlines include pre-applications due by September 4, 2024, and full proposals by December 5, 2024. Interested applicants can reach out to the CDMRP Help Desk at help@eBRAP.org for further assistance.
    CDMRP Neurofibromatosis Investigator-Initiated Research Program
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the Neurofibromatosis Investigator-Initiated Research Program (NFRP) grant to support innovative research projects focused on neurofibromatosis (NF). This program aims to enhance understanding, diagnosis, and treatment of NF1, NF2, and schwannomatosis, with a particular emphasis on improving the quality of life for affected individuals, including military personnel and veterans. The total estimated funding for this initiative is $5.36 million, with up to six awards anticipated, and applications must be submitted by October 3, 2024, following a pre-application deadline of September 12, 2024. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.
    DoD Arthritis Research, Clinical Research Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Materiel Command (USAMRAA), is offering the FY24 Arthritis Research Clinical Research Award (ATRP CRA) to support clinical research aimed at improving the understanding and management of various forms of arthritis, particularly in military personnel and their families. This grant program encourages innovative research proposals that address disease-specific factors and interventions, with a focus on enhancing patient outcomes and informing clinical care or policy. With an estimated total funding of $6 million, the program anticipates awarding approximately three grants, including one for a clinical trial, with applications due by October 30, 2024, and a pre-application deadline of October 16, 2024. Interested applicants can reach out to the CDMRP Help Desk at help@eBRAP.org for further assistance.